Notice of Intent To Grant an Exclusive, Co-Exclusive or Partially Exclusive Patent License, 32284-32285 [2021-12756]

Download as PDF lotter on DSK11XQN23PROD with NOTICES1 32284 Federal Register / Vol. 86, No. 115 / Thursday, June 17, 2021 / Notices Blanton, M.D., 43 FR 27,616, 27,617 (1978). This rule derives from the text of two provisions of the CSA. First, Congress defined the term ‘‘practitioner’’ to mean ‘‘a physician . . . or other person licensed, registered, or otherwise permitted, by . . . the jurisdiction in which he practices . . . , to distribute, dispense, . . . [or] administer . . . a controlled substance in the course of professional practice.’’ 21 U.S.C. 802(21). Second, in setting the requirements for obtaining a practitioner’s registration, Congress directed that ‘‘[t]he Attorney General shall register practitioners . . . if the applicant is authorized to dispense . . . controlled substances under the laws of the State in which he practices.’’ 21 U.S.C. 823(f). Because Congress has clearly mandated that a practitioner possess state authority in order to be deemed a practitioner under the CSA, the DEA has held repeatedly that revocation of a practitioner’s registration is the appropriate sanction whenever he is no longer authorized to dispense controlled substances under the laws of the state in which he practices. See, e.g., James L. Hooper, 76 FR at 71,371–72; Sheran Arden Yeates, M.D., 71 FR 39,130, 39,131 (2006); Dominick A. Ricci, M.D., 58 FR 51,104, 51,105 (1993); Bobby Watts, M.D., 53 FR 11,919, 11,920 (1988); Frederick Marsh Blanton, 43 FR at 27,617. Under Nebraska law, ‘‘[d]ispense means to deliver a controlled substance to an ultimate user or a research subject pursuant to a medical order issued by a practitioner authorized to prescribe, including the packaging, labeling, or compounding necessary to prepare the controlled substance for such delivery.’’ Neb. Rev. Stat. § 28–401(8) (Westlaw, Current through legislation effective May 6, 2021). Further, ‘‘[p]ractitioner means a physician . . . or any other person licensed, registered, or otherwise permitted to distribute, dispense, prescribe, conduct research with respect to, or administer a controlled substance in the course of practice or research in this state . . . .’’ Id. at § 28–401(21). Because Registrant is not currently licensed as a physician, or otherwise licensed, in Nebraska, he is not authorized to dispense controlled substances in Nebraska. Here, the undisputed evidence in the record is that Registrant currently lacks authority to practice medicine in Nebraska. As already discussed, a physician must be a licensed practitioner to dispense a controlled substance in Nebraska. Thus, because Registrant lacks authority to practice medicine in Nebraska and, therefore, is VerDate Sep<11>2014 18:41 Jun 16, 2021 Jkt 253001 not authorized to handle controlled substances in Nebraska, Registrant is not eligible to maintain a DEA registration. Accordingly, I will order that Registrant’s DEA registration be revoked. Order Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No. FK4149882 issued to Tareq A. Khedir Al-Tiae, M.D. Further, pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(f), I hereby deny any pending application of Tareq A. Khedir Al-Tiae, M.D., to renew or modify this registration, as well as any other pending application of Tareq A. Khedir Al-Tiae M.D., for additional registration in Nebraska. This Order is effective July 19, 2021. D. Christopher Evans, Acting Administrator. [FR Doc. 2021–12755 Filed 6–16–21; 8:45 am] BILLING CODE 4410–09–P North Normandy Drive, Petersburg, Virginia 23805–2380, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Controlled substance Methylphenidate ........... Levomethorphan ........... Levorphanol .................. Morphine ....................... Thebaine ....................... Noroxymorphone .......... Tapentadol .................... Drug code 1724 9210 9220 9300 9333 9668 9780 Schedule II II II II II II II The company plans to bulk manufacture the listed controlled substances for the internal use intermediates or for sale to its customers. The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers. No other activities for these drug codes are authorized for this registration. William T. McDermott, Assistant Administrator. [FR Doc. 2021–12812 Filed 6–16–21; 8:45 am] DEPARTMENT OF JUSTICE BILLING CODE P Drug Enforcement Administration NATIONAL AERONAUTICS AND SPACE ADMINISTRATION [Docket No. DEA–852] Bulk Manufacturer of Controlled Substances Application: AMPAC Fine Chemicals Virginia, LLC Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 Notice of Intent To Grant an Exclusive, Co-Exclusive or Partially Exclusive Patent License National Aeronautics and Space Administration. ACTION: Notice of intent to grant exclusive, co-exclusive or partially exclusive patent license. AGENCY: AMPAC Fine Chemicals Virginia, LLC. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 16, 2021. Such persons may also file a written request for a hearing on the application on or before August 16, 2021. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on May 5, 2021, AMPAC Fine Chemicals Virginia, LLC., 2820 SUMMARY: [Notice: (21–035)] NASA hereby gives notice of its intent to grant an exclusive, coexclusive or partially exclusive patent license to practice the inventions described and claimed in the patents and/or patent applications listed in SUPPLEMENTARY INFORMATION below. DATES: The prospective exclusive, coexclusive or partially exclusive license may be granted unless NASA receives written objections including evidence and argument, no later than July 2, 2021 that establish that the grant of the license would not be consistent with the requirements regarding the licensing of federally owned inventions as set forth in the Bayh-Dole Act and implementing regulations. Competing applications completed and received by NASA no later than July 2, 2021 will also be treated as objections to the grant of the contemplated exclusive, co-exclusive or SUMMARY: E:\FR\FM\17JNN1.SGM 17JNN1 Federal Register / Vol. 86, No. 115 / Thursday, June 17, 2021 / Notices partially exclusive license. Objections submitted in response to this notice will not be made available to the public for inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act. FOR FURTHER INFORMATION CONTACT: Written objections relating to the prospective license or requests for further information may be submitted to Agency Counsel for Intellectual Property, NASA Headquarters at Email: hq-patentoffice@mail.nasa.gov. Questions may be directed to Helen Galus at (202) 358–3437. SUPPLEMENTARY INFORMATION: NASA intends to grant an exclusive, coexclusive, or partially exclusive patent license in the United States to practice the inventions described and claimed in: US 8,735,116 B2, High-Density Spot Seeding for Tissue Model Formation and US 9,243,223 B2, High-Density Spot Seeding for Tissue Model Formation to BSK Health Partners, LLC. having its principal place of business in North Richland Hills, Texas. The fields of use may be limited. NASA has not yet made a final determination to grant the requested license and may deny the requested license even if no objections are submitted within the comment period. This notice of intent to grant an exclusive, co-exclusive or partially exclusive patent license is issued in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i). The patent rights in these inventions have been assigned to the United States of America as represented by the Administrator of the National Aeronautics and Space Administration. The prospective license will comply with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Information about other NASA inventions available for licensing can be found online at http:// technology.nasa.gov. Helen M. Galus, Agency Counsel for Intellectual Property. BILLING CODE 7510–13–P NUCLEAR REGULATORY COMMISSION lotter on DSK11XQN23PROD with NOTICES1 Advisory Committee on the Medical Uses of Isotopes: Meeting Notice U.S. Nuclear Regulatory Commission. ACTION: Notice of meeting. AGENCY: The U.S. Nuclear Regulatory Commission (NRC) will convene a public teleconference meeting of the VerDate Sep<11>2014 18:41 Jun 16, 2021 Jkt 253001 The teleconference meeting will be held on Thursday, July 15, 2021, 1:00 p.m. to 3:00 p.m. Eastern Daylight Time. DATES: Date Webinar information July 15, 2021 .... Link: https:// usnrc.webex.com. Event number: 199 085 4780. 2. Questions and comments from members of the public will be permitted during the meeting, at the discretion of the ACMUI Chairman. 3. The draft transcript and meeting summary will be available on ACMUI’s website https://www.nrc.gov/readingrm/doc-collections/acmui/meetings/ 2021.html on or about August 31, 2021. 4. Persons who require special services, such as those for the hearing impaired, should notify Ms. Jamerson of their planned participation. This meeting will be held in accordance with the Atomic Energy Act of 1954, as amended (primarily Section 161a); the Federal Advisory Committee Act (5 U.S.C. App); and the Commission’s regulations in 10 CFR part 7. Dated at Rockville, Maryland this 14th day of June, 2021. For the U.S. Nuclear Regulatory Commission. Russell E. Chazell, Federal Advisory Committee Management Officer. [FR Doc. 2021–12767 Filed 6–16–21; 8:45 am] BILLING CODE 7590–01–P Public Participation: The meeting will also be held as a webinar. Any member of the public who wishes to participate in any portion of this meeting should register in advance of the meeting by accessing the provided link and event number above. Upon successful registration, an email confirmation will be generated providing the telephone bridge line and a link to join the webinar on the day of the meeting. Members of the public should also monitor the NRC’s Public Meeting Schedule at https://www.nrc.gov/pmns/ mtg for any meeting updates. If there are any questions regarding the meeting, please contact Ms. Jamerson using the information below. Contact Information: Kellee Jamerson, email: Kellee.Jamerson@nrc.gov, telephone: 301–415–7408. Conduct of the Meeting [FR Doc. 2021–12756 Filed 6–16–21; 8:45 am] SUMMARY: Advisory Committee on the Medical Uses of Isotopes (ACMUI) on July 15, 2021, to discuss the ACMUI Subcommittee on Extravasations and Medical Event Reporting draft report on the NRC staff’s preliminary evaluation of whether extravasations merits a change in medical event reporting. The meeting agenda is subject to change. Meeting information, including a copy of the agenda and related documents, will be available on the ACMUI’s Meetings and Related Documents web page at https://www.nrc.gov/reading-rm/ doc-collections/acmui/meetings/ 2021.html. The agenda and related meeting documents may also be obtained by contacting Ms. Kellee Jamerson using the information below. 32285 The ACMUI Chair, Darlene F. Metter, M.D., will preside over the meeting. Dr. Metter will conduct the meeting in a manner that will facilitate the orderly conduct of business. The following procedures apply to public participation in the meeting: 1. Persons who wish to provide a written statement should submit an electronic copy to Ms. Jamerson at the contact information listed above. All written statements must be received by July 12, 2021, three business days prior to the meeting, and must pertain to the topics on the agenda for the meeting. PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 NUCLEAR REGULATORY COMMISSION [Docket No. 40–8907; NRC–2019–0026] United Nuclear Corporation Church Rock Project Nuclear Regulatory Commission. ACTION: Draft environmental impact statement; reopening of comment period. AGENCY: On November 13, 2020, the U.S. Nuclear Regulatory Commission (NRC) issued for public comment a draft Environmental Impact Statement (EIS) for United Nuclear Corporation’s (UNC) license amendment request. The public comment period closed on May 27, 2021. The NRC has decided to re-open the public comment period to allow more time for members of the public to develop and submit their comments. UNC is requesting authorization to amend its license (SUA–1475) to excavate approximately 1 million cubic yards (CY) of mine waste from the Northeast Church Rock Mine Site and dispose of it at the existing mill site in McKinley County, New Mexico. The NRC plans to hold a public meeting in the future to promote full understanding of the contemplated action and facilitate public comment. DATES: The comment period for the document published on November 13, SUMMARY: E:\FR\FM\17JNN1.SGM 17JNN1

Agencies

[Federal Register Volume 86, Number 115 (Thursday, June 17, 2021)]
[Notices]
[Pages 32284-32285]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12756]


=======================================================================
-----------------------------------------------------------------------

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice: (21-035)]


Notice of Intent To Grant an Exclusive, Co-Exclusive or Partially 
Exclusive Patent License

AGENCY: National Aeronautics and Space Administration.

ACTION: Notice of intent to grant exclusive, co-exclusive or partially 
exclusive patent license.

-----------------------------------------------------------------------

SUMMARY: NASA hereby gives notice of its intent to grant an exclusive, 
co-exclusive or partially exclusive patent license to practice the 
inventions described and claimed in the patents and/or patent 
applications listed in SUPPLEMENTARY INFORMATION below.

DATES: The prospective exclusive, co-exclusive or partially exclusive 
license may be granted unless NASA receives written objections 
including evidence and argument, no later than July 2, 2021 that 
establish that the grant of the license would not be consistent with 
the requirements regarding the licensing of federally owned inventions 
as set forth in the Bayh-Dole Act and implementing regulations. 
Competing applications completed and received by NASA no later than 
July 2, 2021 will also be treated as objections to the grant of the 
contemplated exclusive, co-exclusive or

[[Page 32285]]

partially exclusive license. Objections submitted in response to this 
notice will not be made available to the public for inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act.

FOR FURTHER INFORMATION CONTACT: Written objections relating to the 
prospective license or requests for further information may be 
submitted to Agency Counsel for Intellectual Property, NASA 
Headquarters at Email: [email protected]. Questions may be 
directed to Helen Galus at (202) 358-3437.

SUPPLEMENTARY INFORMATION: NASA intends to grant an exclusive, co-
exclusive, or partially exclusive patent license in the United States 
to practice the inventions described and claimed in: US 8,735,116 B2, 
High-Density Spot Seeding for Tissue Model Formation and US 9,243,223 
B2, High-Density Spot Seeding for Tissue Model Formation to BSK Health 
Partners, LLC. having its principal place of business in North Richland 
Hills, Texas. The fields of use may be limited. NASA has not yet made a 
final determination to grant the requested license and may deny the 
requested license even if no objections are submitted within the 
comment period.
    This notice of intent to grant an exclusive, co-exclusive or 
partially exclusive patent license is issued in accordance with 35 
U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i). The patent rights in these 
inventions have been assigned to the United States of America as 
represented by the Administrator of the National Aeronautics and Space 
Administration. The prospective license will comply with the 
requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Information about other NASA inventions available for licensing can 
be found online at http://technology.nasa.gov.

Helen M. Galus,
Agency Counsel for Intellectual Property.
[FR Doc. 2021-12756 Filed 6-16-21; 8:45 am]
BILLING CODE 7510-13-P